Cumberland Pharmaceuticals announces Phase 2 ASSIST-SSc study data for oral ifetroban

Cumberland Pharmaceuticals announced data from its Phase 2 ASSIST-SSc study of oral ifetroban for patients with systemic sclerosis. Gastrointestinal adverse events were more frequent in the ifetroban group than placebo, and limited disease progression in most patients reduced the ability to track treatment differences.

Detected & updated continuously · Source: Nebula